RadNet (RDNT) has drawn investor attention after its recent share price moves, with the stock closing at US$76.86 and posting double digit total returns over the past month and past 3 months.

Zooming out, RadNet’s recent share price momentum, including a 24.83% 30 day share price return and 42.76% 90 day share price return, sits alongside an 8.33% year to date share price return and a 135.26% 3 year total shareholder return. Together, these figures indicate building momentum from a longer running positive trend.

Scan beyond RadNet’s recent surge and compare it with hand picked healthcare imaging and AI peers using the 42 healthcare AI stocks.

After RadNet’s sharp move, some investors will prefer to wait for a pullback, while others may see current levels as reasonable. The next step is to see what the underlying valuation signals suggest.

Most Popular Narrative: 17.2% Undervalued

RadNet's most followed valuation narrative places fair value at $92.88 per share, compared with the recent close at $76.86, which frames a clear pricing gap for investors to assess.

Ongoing investments in AI-powered imaging solutions (e.g., DeepHealth, See-Mode, iCAD) are materially increasing center throughput, boosting capacity utilization, and driving more high-margin advanced procedures, directly enhancing both revenue growth and EBITDA margins as adoption scales through 2026.

Read the complete narrative. Read the complete narrative.

Want to see what is baked into that fair value for RadNet? The narrative leans on rapid earnings improvement, steadier revenue expansion, and a richer profit profile than today. The projected earnings multiple is aggressive. The story hangs on whether those margin and growth assumptions hold up.

Result: Fair Value of $92.88 (UNDERVALUED)

However, RadNet’s story can still be knocked off course if heavy AI and digital health spending strains cash flow, or if reimbursement and payer contracts turn less favorable.

Another View: What RadNet’s Sales Multiple Is Saying

The RadNet narrative leans on a fair value of $92.88, yet the share price currently reflects a P/S ratio of 2.7x. That is higher than both the US Healthcare industry average of 1.5x and an estimated fair ratio of 1.1x, which points to meaningful valuation risk if sentiment cools.

Investors weighing RadNet’s upside story against this richer sales multiple may want to stress test their own assumptions on margins, growth and competitive pressure before taking a strong view. See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

Unsure how to balance RadNet’s upbeat narrative with the caution around risks and valuation signals? Act while the information is fresh and shape your own view by weighing the 3 key rewards and 2 important warning signs

Looking for more investment ideas beyond RadNet?

Do not stop your research with RadNet. Use fresh ideas from focused stock lists to pressure test your thinking and spot opportunities you might otherwise miss.

• Hunt for mispriced quality by scanning companies that show up in the 49 high quality undervalued stocks.
• Strengthen your defense with businesses that feature on the 74 resilient stocks with low risk scores and aim for steadier ride potential.
• Back robust balance sheets by checking the list of solid balance sheet and fundamentals (51 results) and focus on companies with financial resilience.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.